CTRI/2023/09/058019已完成Phase 3 4
A two-arm, randomized, double-blinded, placebo-controlled, parallel study to evaluate the efficacy and safety of Beta Amyrin Palmitate in newly diagnosed patients of type 2 diabetes mellitus associated with dyslipidaemia.
Sam Sabinsa Group Limited2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年9月30日最近更新:
试验速览
- 阶段
- Phase 3 4
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- To assess the efficacy of Beta Amyrin Palmitate on blood glucose level.
研究概览
简要总结
The study involves 30 subjects randomized in two arms and will receive 90 days of treatment and telephonic follow-up after 7 days following the last visit. Participants will be randomized to receive either Beta Amyrin Palmitate or Placebo (Microcrystalline Cellulose). Specific biomarkers like fasting blood sugar, serum insulin, HbA1c will be measured and analysed during the study period. The final statistical analysis and study report will be complied at the end of the study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
入排标准
- 年龄范围
- 25.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Participants should be willing to give a written informed consent.
- •2.Participants should be willing to comply with the requirements of the trial/ study.
- •3.Male and female participants aged between 25-65 years.
- •4.Females with childbearing potential who agree to use a barrier method of contraception throughout the study period.
- •5.Participants, newly diagnosed with Type 2 Diabetes (T2DM) and is drug naive with FBS between 126 to 210 mg/dL, PPBS between 200 to 300 mg/dL and HbA1c between 6.5 to 8.9 %.
- •6.Lipid parameters: Total Cholesterol between 200 to 300 mg/dL, Triglyceride between 160 to 300 mg/dL and LDL between 120 to 200 mg/dL.
- •7.Ability to swallow and retain oral medications as per the protocol.
排除标准
- •History of Smoking and Alcohol intake (within 3 months before screening)
- •Type-1 Diabetes
- •Presence of chronic gastrointestinal diseases, severe immune deficiencies, lactose intolerance.
- •Use of any lipid lowering therapies in the past 3 months.
- •Patients on antihypertensive medications.
- •Patient with history of clinically significant thyroid disorder, gastrointestinal, cardiovascular, haematological, hepatic, renal, respiratory, active malignancies or genitourinary abnormalities or diseases.
- •Patient who has participated in any clinical trial within the past 3 months.
- •Pregnant and lactating women and those not willing to follow a reliable and effective contraceptive measure during the study.
- •Any planned surgery during the study.
- •A history of significant multiple and/or severe allergies or anaphylactic reactions.
- •Patient with known history of hypersensitivity to the investigational product.
- •Participant who has participated in any clinical trial within the last 3 months.
- •Any other condition that the Principal Investigator thinks may jeopardize the study.
- •Any other reason(s) as per principal investigator discretion.
结局指标
主要结局
To assess the efficacy of Beta Amyrin Palmitate on blood glucose level.
时间窗: 1. Screening to 90 days | 2. Screening to 90 days
1. Mean change in HbA1c from screening to final visit.
时间窗: 1. Screening to 90 days | 2. Screening to 90 days
2. Mean change in fasting blood glucose & postprandial blood sugar from screening to final visit.
时间窗: 1. Screening to 90 days | 2. Screening to 90 days
次要结局
- To compare Mean change in lipid profile- Triglycerides, low density lipid, very low-density lipid, high density lipid & total cholesterol.(2. To compare the mean change in HbA1c, Fasting Blood Glucose and Post-prandial blood sugar.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
Phase 3 4
To test the product with curcumin-based derivative in patients with joints pain of kneeCTRI/2023/11/060117Sami Sabinsa Group Limited60
招募中
Phase 3 4
Flavinergy (extract of Black-Thai Ginger) on metabolic health of overweight adultsCTRI/2023/09/058149Sam Sabinsa Group Limited80
招募中
Phase 3 4
Activity of Curcumin derivative on Joint Inflammation (knees) of the patients.CTRI/2023/09/058104Sam Sabinsa Group Limited96
已完成
3 期
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseNCT00286897Eisai Limited702
已完成
Phase 3 4
β-amyrin Palmitate with Activated Curcumin Complex combination versus Metformin in newly diagnosed patients of type 2 diabetes mellitus associated with dyslipidemiaCTRI/2023/09/057969Sam Sabinsa Group Limited96